ALX Oncology
NEWS
With recent high-profile failures, experts say safety concerns and a lack of diversification are hindering the field—but still hold out hope for an approval.
The clinical-stage company joins several others in the anti-CD47 space which have dropped studies amid poor results, including Gilead Sciences’ decision late last month to stop a Phase III trial.
Due to the registration potential of the mid-stage studies, the U.S. Food and Drug Administration requested the company complete a standard safety study, which amounts to a partial clinical hold on the study.
ALX Oncology will partner with pharma giant Merck to evaluate a combination of its CD47 inhibitor with Keytruda as a potential treatment for patients with Head & Neck Squamous Cell Carcinoma.
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
IN THE PRESS